


-77-

WE CLAIM:

1. The compounds of Formula I:



I


where:

R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

10 R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxy carbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

15 R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



(i)

-78-

n is 0, 1, or 2;

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

5 R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

10 R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;


R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

15 or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

20 b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

2. A pharmaceutical formulation which comprises, in association with a pharmaceutically acceptable carrier, 25 diluent or excipient, a compound of Formula I:



-79-

where:


R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

5 R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

10 R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



15

(i)

n is 0, 1, or 2;

20 R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

25 R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q

-80-

taken together with the carbon atoms to which they are attached form a double bond;


$R^{7'}$ is hydrogen or methyl, provided that $R^{7'}$ may be methyl only when R^7 is other than hydrogen;

5 or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R^5 , R^6 , and R^7 , must be other than hydrogen; and

b) no more than two of R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , and $R^{7'}$
10 may be other than hydrogen.

3. A method for increasing activation of the 5-HT_{2C} receptor in mammals, comprising administering to a mammal in need of such activation a pharmaceutically effective amount
15 of a compound of Formula I:



where:

R is hydrogen, halo, trifluoromethyl or C_1 - C_6 alkyl;


R^1 is hydrogen, halo, trifluoromethyl, phenyl, or C_1 - C_6
20 alkyl;

R^2 , R^3 , and R^4 are independently hydrogen, halo, trifluoromethyl, cyano, C_1 - C_4 alkoxy, C_1 - C_4 alkoxycarbonyl, C_1 - C_6 alkyl, C_1 - C_6 alkyl substituted with a substituent selected from the group consisting of C_1 - C_4 alkoxy and
25 hydroxy, or $-C(O)NHR^9$;

-81-

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the
5 benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

10 R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q
15 taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q
20 attached form a double bond;

R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;


or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

25 a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

-82-

4. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



I

where:


R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



-83-

(i)

n is 0, 1, or 2;

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

5 Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

10 R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;


R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

15 or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

20 b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

5. A method for the treatment of depression in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



-84-

where:


R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

5 R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

10 R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



15

(i)

n is 0, 1, or 2;

20 R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

25 R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q

-85-

taken together with the carbon atoms to which they are attached form a double bond;

$R^{7'}$ is hydrogen or methyl, provided that $R^{7'}$ may be methyl only when R^7 is other than hydrogen;

5 or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R^5 , R^6 , and R^7 , must be other than hydrogen; and

b) no more than two of R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , and $R^{7'}$
10 may be other than hydrogen.

~~Sub A2~~ 6. A method of any of Claims 3, 4, or 5 where the
mammal is human.

~~ALL A3~~